Citius Oncology (CTOR) Cost of Revenue (2025 - 2026)

Citius Oncology (CTOR) recorded quarterly Cost of Revenue of $328878.0 in Q1 2026, down 58.33% quarter-over-quarter from $789208.0 in Q4 2025.

Citius Oncology (CTOR) Cost of Revenue (2025 - 2026) Analysis & Trends

Citius Oncology's Cost of Revenue history runs 2 years deep, the most recent figure standing at $328878.0 for Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cost of Rev (Qtr)
1	Teva Pharmaceutical Industries	38.77 Bn	35.04 Bn	1.97 Bn	696.00 Mn
2	Zoetis	34.11 Bn	32.16 Bn	1.62 Bn	641.00 Mn
3	United Therapeutics	23.68 Bn	21.53 Bn	648.10 Mn	133.40 Mn
4	Aurora Cannabis	16.48 Bn	16.40 Bn	33.43 Mn	34.44 Mn
5	Neurocrine Biosciences	16.19 Bn	14.88 Bn	800.70 Mn	13.80 Mn
6	Elanco Animal Health	11.44 Bn	11.01 Bn	785.00 Mn	586.00 Mn
7	Alkermes	7.28 Bn	6.77 Bn	-116.06 Mn	155.56 Mn
8	Lantheus Holdings	6.48 Bn	5.98 Bn	230.92 Mn	52.68 Mn
9	Hims & Hers Health	6.35 Bn	5.60 Bn	396.79 Mn	222.00 Mn
10	Citius Oncology	68.02 Mn	65.39 Mn	1.34 Mn	328,878.00

Download Data